These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12640094)

  • 1. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa.
    Müller T; Woitalla D; Kuhn W
    J Neurol Neurosurg Psychiatry; 2003 Apr; 74(4):549. PubMed ID: 12640094
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse reactions to levodopa: drug toxicity or progression of disease?
    Agid Y; Chase T; Marsden D
    Lancet; 1998 Mar; 351(9106):851-2. PubMed ID: 9525359
    [No Abstract]   [Full Text] [Related]  

  • 3. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical treatment of Parkinson's disease.
    Ahlskog JE
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract]   [Full Text] [Related]  

  • 6. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 7. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
    Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F
    Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimising levodopa therapy.
    Abbruzzese G
    Neurol Sci; 2008 Dec; 29 Suppl 5():S377-9. PubMed ID: 19381767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacotherapy of Parkinson's disease].
    Ceballos-Baumann A
    MMW Fortschr Med; 2013 May; 155(8):49-51. PubMed ID: 24437138
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
    Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
    Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 13. Case study: cerebrovascular parkinsonism with levodopa addiction.
    Lily O; Al-Din A
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1365-6. PubMed ID: 15314141
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 15. Welcome news about levodopa, but uncertainty remains.
    Fahn S
    Ann Neurol; 1998 May; 43(5):551-4. PubMed ID: 9585348
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Deleu D; Hanssens Y
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16721952
    [No Abstract]   [Full Text] [Related]  

  • 17. Individualization of drug therapy for the parkinsonian patient.
    JAMA; 1975 Sep; 233(11):1198-201. PubMed ID: 240043
    [No Abstract]   [Full Text] [Related]  

  • 18. Zotepine in levodopa-induced Psychosis.
    Spieker S; Stetter F; Klockgether T
    Mov Disord; 1995 Nov; 10(6):795-7. PubMed ID: 8750001
    [No Abstract]   [Full Text] [Related]  

  • 19. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
    Yasui K; Nakaso K; Kowa H; Takeshima T; Nakashima K
    Acta Neurol Scand; 2003 Jul; 108(1):66-7. PubMed ID: 12807397
    [No Abstract]   [Full Text] [Related]  

  • 20. A risk-benefit assessment of drugs used in the management of Parkinson's disease.
    Bodagh IY; Robertson DR
    Drug Saf; 1994 Aug; 11(2):94-103. PubMed ID: 7946003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.